Short Interest in Harvard Bioscience, Inc. (NASDAQ:HBIO) Drops By 6.2%

Harvard Bioscience, Inc. (NASDAQ:HBIO) saw a large decline in short interest in November. As of November 15th, there was short interest totalling 374,100 shares, a decline of 6.2% from the October 31st total of 398,900 shares. Based on an average trading volume of 136,800 shares, the days-to-cover ratio is presently 2.7 days.

Harvard Bioscience Stock Up 4.5 %

Shares of Harvard Bioscience stock traded up $0.10 during trading on Tuesday, reaching $2.30. 84,735 shares of the company traded hands, compared to its average volume of 119,977. The firm has a market capitalization of $100.33 million, a PE ratio of -6.67 and a beta of 1.27. Harvard Bioscience has a 1-year low of $1.99 and a 1-year high of $5.56. The company has a 50 day moving average price of $2.39 and a 200-day moving average price of $2.77. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.06 and a quick ratio of 0.91.

Institutional Trading of Harvard Bioscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. increased its holdings in shares of Harvard Bioscience by 193.9% during the second quarter. Assenagon Asset Management S.A. now owns 227,701 shares of the medical instruments supplier’s stock valued at $649,000 after acquiring an additional 150,218 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Harvard Bioscience by 13.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 274,635 shares of the medical instruments supplier’s stock valued at $783,000 after purchasing an additional 31,505 shares in the last quarter. Vanguard Group Inc. raised its holdings in Harvard Bioscience by 2.4% during the first quarter. Vanguard Group Inc. now owns 2,152,147 shares of the medical instruments supplier’s stock worth $9,125,000 after buying an additional 49,576 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Harvard Bioscience by 6.1% during the second quarter. Renaissance Technologies LLC now owns 745,278 shares of the medical instruments supplier’s stock valued at $2,124,000 after buying an additional 42,800 shares during the last quarter. Finally, Rhumbline Advisers increased its position in shares of Harvard Bioscience by 24.9% during the second quarter. Rhumbline Advisers now owns 47,753 shares of the medical instruments supplier’s stock worth $136,000 after acquiring an additional 9,512 shares in the last quarter. 80.87% of the stock is owned by institutional investors.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.